Gsk (GSK) EBIT Margin (2009 - 2026)
Gsk (GSK) posted quarterly EBIT Margin of 5.72% for Q2 2026, down 1961.0% year-over-year from 0.31% in Q2 2025, and down 80.97% quarter-over-quarter from 30.06% in Q1 2026.
Gsk (GSK) EBIT Margin (2009 - 2026) Analysis & Trends
Gsk's EBIT Margin history runs 18 years deep, the most recent figure standing at 5.72% for Q2 2026.
- In Q2 2026, EBIT Margin fell 1961.0% year-over-year to 5.72%; the TTM figure through Jun 2026 stood at 23.97% (up 448.0% YoY), while the FY2025 annual figure was 24.28%, up 1147.0% from the prior year.
- EBIT Margin for Q2 2026 stood at 5.72%, down from 30.06% in the prior quarter.
- The five-year high for EBIT Margin was 31.89% in Q1 2022, with the low at 2.36% in Q3 2024.
- The 5-year median for EBIT Margin is 24.63% (2025), against an average of 22.92%.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin sank 2156 bps in 2024, then jumped 2798 bps in 2025.
- Gsk's EBIT Margin stood at 23.9% in 2022, then gained by 25 bps to 29.89% in 2023, then slumped by 31 bps to 20.57% in 2024, then soared by 33 bps to 27.34% in 2025, then plunged by 79 bps to 5.72% in 2026.
- Business Quant data shows GSK's EBIT Margin at 5.72% in Q2 2026, 30.06% in Q1 2026, and 27.34% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.21 Bn | 633.45 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 468.90 Bn | 462.33 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 378.18 Bn | 371.04 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 302.34 Bn | 294.65 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 257.60 Bn | 252.70 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 236.39 Bn | 222.40 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 182.58 Bn | 179.41 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 161.17 Bn | 149.47 Bn | 10.94 Bn | 28.37% |
| 9 | Gsk | 105.37 Bn | 101.20 Bn | 8.24 Bn | 5.72% |
| 10 | Sanofi | 54.98 Bn | 47.60 Bn | 10.79 Bn | 124.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.72% |
| Mar 31, 2026 | 30.06% |
| Dec 31, 2025 | 27.34% |
| Sep 30, 2025 | 30.34% |
| Jun 30, 2025 | 25.33% |
| Mar 31, 2025 | 29.48% |
| Dec 31, 2024 | 20.57% |
| Sep 30, 2024 | 2.36% |
| Jun 30, 2024 | 20.88% |
| Mar 31, 2024 | 20.24% |
| Dec 31, 2023 | 29.89% |
| Sep 30, 2023 | 23.92% |
| Jun 30, 2023 | 29.83% |
| Mar 31, 2023 | 29.95% |
| Dec 31, 2022 | 23.90% |
| Sep 30, 2022 | 15.21% |
| Jun 30, 2022 | 15.60% |
| Mar 31, 2022 | 31.89% |
| Dec 31, 2021 | 10.06% |
| Sep 30, 2021 | 20.82% |